Foundayo vs. Zepbound: How do they compare for weight loss?

In this article:

• Foundayo vs. Zepbound key differences
• Conditions treated
• How to take Foundayo
• How to take Zepbound
• Which is better?
• Insurance and cost comparison
• Side effects
• Interactions and warnings
• Expert takeaway
• FAQs

In this article

• Foundayo vs. Zepbound key differences
• Conditions treated
• How to take Foundayo
• How to take Zepbound
• Which is better?
• Insurance and cost comparison
• Side effects
• Interactions and warnings
• Expert takeaway
• FAQs

Foundayo (orforglipron) and Zepbound (tirzepatide) have been approved by the Food and Drug Administration (FDA) for weight loss. Both decrease appetite and help people feel full longer, but they have meaningful differences in convenience and effectiveness. This guide covers similarities and differences between Foundayo vs. Zepbound so you can discuss each option with a healthcare provider. 

Key differences

Zepbound is a once-weekly injectable prescription medication for weight loss. It works by targeting two hormone pathways, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and has helped people lose an average of 21% body weight in clinical trials. Foundayo is a once-daily oral GLP-1 pill that helps people lose an average of 12% body weight. 

Compare Foundayo vs. Zepbound key differences
Feature	Foundayo (orforglipron)	Zepbound (tirzepatide)
Drug class	Non-peptide small-molecule GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Manufacturer	Eli Lilly	Eli Lilly
FDA approval (weight loss)	April 2026	November 2023
Dosage form	Oral tablet (daily)	Subcutaneous injection (weekly)
Dosing restrictions	Titration required. Take any time of day, with or without food. No more than 9 mg once per day when taken with strong CYP3A4 inhibitors.	Titration required. Take any time of day, with or without food. Must be comfortable with self-injection.
Average weight loss (highest dose, clinical trial)	About 12% body weight over 72 weeks	About 21% body weight over 72 weeks

Conditions treated

Both Foundayo and Zepbound are FDA approved for weight loss and weight management alongside a reduced-calorie diet and increased physical activity in adults with a BMI of at least 27. If your BMI is lower than 30, you must have at least one weight-related health condition.

Zepbound is also FDA approved to treat moderate to severe obstructive sleep apnea in adults with a BMI of 30 or higher.

Compare Foundayo vs. Zepbound conditions treated
Indication	Foundayo	Zepbound
Chronic weight management (obesity)	FDA approved for adults with a BMI of 30 or higher	FDA approved for adults with a BMI of 30 or higher
Chronic weight management (overweight)	FDA approved for adults with a BMI of 27 or higher with at least one weight-related health condition	FDA approved for adults with a BMI of 25 or higher with at least one weight-related health condition
Type 2 diabetes	Not approved	Not approved, however, Mounjaro (same drug, different brand) is FDA approved for Type 2 diabetes
Obstructive sleep apnea (OSA)	Not approved	FDA approved for adults with moderate to severe OSA and a BMI of 30 or higher

How to take Foundayo

Foundayo is an oral tablet that’s taken once per day with or without food. The tablets should be swallowed whole and never split, crushed, or chewed.

To reduce the risk of side effects, Foundayo is started at a low dose that’s gradually increased over several months. Your healthcare provider will typically follow this schedule, increasing the dose after at least 30 days at each step:

• 0.8 mg once per day for 30 days
• 2.5 mg once per day for 30 days
• 5.5 mg once per day for 30 days
• 9 mg once per day for 30 days
• 14.5 mg once per day for 30 days
• 17.2 mg once per day (the maximum dose)

Your healthcare provider may recommend staying on a lower dose of Foundayo if you take certain medications or experience side effects on higher doses.

Foundayo should be stored in the dark at room temperature (about 68 to 77 degrees Fahrenheit). 

How to take Zepbound

Zepbound is a once-weekly injection. Your healthcare provider will show you how to properly inject Zepbound under the skin of your abdomen, thigh, or upper arm using a single-dose pen or a vial and syringe. You can take Zepbound at any time of day, with or without food.

Everyone starts Zepbound by taking 2.5 mg once per week for at least four weeks. The dose is then increased by 2.5 mg every four weeks until you reach the maximum Zepbound dosage of 15 mg once per week.

Side effects tend to appear when the dose is increased, but they often go away over the next few weeks. If side effects persist, a healthcare provider may recommend lowering the dose. You don’t have to take the maximum dose of 15 mg to see results with Zepbound.

Store Zepbound in the refrigerator between 36 and 46 degrees Fahrenheit, and don’t store it in the freezer. If needed, Zepbound can be kept at room temperature for up to 21 days and must be used or discarded after that.

Is Zepbound better than Foundayo for weight loss?  

Yes, Zepbound is more effective than Foundayo for weight loss in clinical trials, though the two haven’t been compared head-to-head. 

In clinical trials, Zepbound produced greater average weight loss than Foundayo. People lost an average of 21% of their body weight after taking Zepbound for 72 weeks, while people who took Foundayo for 72 weeks lost about 12% on average. 

Based on the average starting weight of trial participants, that works out to roughly 48 pounds with Zepbound and about 25 pounds with Foundayo, on average. These results were achieved alongside a reduced-calorie diet and increased physical activity of at least 150 minutes per week. Because Foundayo and Zepbound haven’t been compared directly in a head-to-head trial, these figures come from separate studies, and individual results will vary. 

“Foundayo can produce meaningful weight loss, but it technically doesn’t outperform Zepbound in that department,” says Fernando Ovalle Jr., MD, an Orlando-based obesity medicine specialist with Drugwatch.com. “Clinically, I’d present it as an important new option, especially for patients who want an oral medication, but not necessarily the strongest option for every patient.” 

Foundayo vs. Zepbound: Insurance coverage and cost comparison

Zepbound is more likely to be covered by health insurance than Foundayo because it’s been on the market longer. The FDA approved Zepbound for weight loss on Nov. 8, 2023. Foundayo received FDA approval two and a half years later, on April 1, 2026.

Despite Foundayo’s recent approval, the largest pharmacy benefit managers (PBMs) in the U.S. have already added it to their formularies. Zepbound is also covered by these PBMs. CVS Caremark had previously dropped Zepbound, but announced in late May 2026 that it would restore coverage, with Zepbound returning to its standard commercial formulary on Oct. 1, 2026.

Although these are positive signs, coverage for Zepbound and Foundayo ultimately varies by plan. Plan sponsors, such as employers, can choose not to cover weight loss medications. Veterans Affairs covers Zepbound only to treat obstructive sleep apnea and doesn’t cover Foundayo at all. Medicaid coverage varies by state.

There’s one program where access to Foundayo and Zepbound doesn’t depend on your specific plan: Medicare. From July 1, 2026, through Dec. 31, 2027, eligible Medicare Part D beneficiaries can get certain GLP-1 medications, including Foundayo and Zepbound, for a $50 copay per month through the Medicare GLP-1 Bridge. A prior authorization is required.

Zepbound costs less than Foundayo for out-of-pocket payers. Zepbound retails for an average of $665 per 1, 2.4 milliliter (mL) of 2.5 milligram (mg)/0.6 mL kwikpen, whereas Foundayo averages $857 per 30, 0.8 mg tablets.

A free SingleCare prescription discount card lowers the cash price of Zepbound to $409 per 1, 2.4 mL of 2.5 mg/0.6 mL kwikpen. Foundayo costs as low as $602 per 30, 0.8 mg tablets with a SingleCare card. SingleCare prices can vary by quantity, dosage, form, and pharmacy.

Compare Foundayo vs. Zepbound cost & coverage
Coverage details	Foundayo	Zepbound
Typically covered by insurance?	Varies by plan	Varies by plan
Typically covered by Medicare Part D?	Yes, through Medicare GLP-1 Bridge	Yes, through Medicare GLP-1 Bridge
Typically covered by Medicaid?	Varies by state	Varies by state
SingleCare cost	$602 per 30, 0.8 mg tablets at Kroger	$409 per 1, 2.4 mL of 2.5 mg/0.6 mL Kwikpen at Kroger
How to save with SingleCare	Get coupon	Get coupon

 

Foundayo vs. Zepbound side effects

Nausea, diarrhea, vomiting, and constipation are the most common Zepbound side effects, and they’re the most common Foundayo side effects too. These tend to occur more often at higher doses of either medication, so the rates below reflect the higher doses studied in clinical trials. 

• Nausea is the most common side effect of both medications, occurring in as many as 35% of Foundayo patients and 29% of Zepbound patients.
• Diarrhea occurs in as many as 25% of Foundayo patients and 23% of Zepbound patients.
• Vomiting occurs nearly twice as often with Foundayo (as many as 24% of patients) as with Zepbound (13%).
• Constipation is most common at mid-range doses of Foundayo (as many as 27%) and lower doses of Zepbound (17%).

Foundayo and Zepbound share other possible side effects, including:

• Indigestion
• Abdominal pain or distension
• Fatigue
• Burping or passing gas
• Hair loss
• Gastroesophageal Reflux Disease (GERD)

Foundayo increases the risk of headache, while Zepbound may cause dizziness, low blood pressure, or injection site reactions. Each of these occurs in fewer than 9% of patients. This isn’t a complete list of possible side effects. Talk to a healthcare provider or pharmacist if you have questions about specific Zepbound or Foundayo side effects. 

How bad are Foundayo side effects compared to Zepbound?

In Foundayo clinical trials, most people who experienced gastrointestinal (GI) side effects, including nausea, diarrhea, vomiting, and constipation, described them as mild (60%). About 6% of patients stopped using Foundayo because of GI side effects.

Zepbound clinical trial data doesn’t include information about side effect severity, but fewer than 5% of patients stopped using Zepbound because of GI side effects. Discontinuation rates are broadly similar between the two medications, though the drugs haven’t been compared directly, so the figures come from separate trials.

Rare but serious side effects

People taking Zepbound or Foundayo run the risk of experiencing nine rare but serious side effects:

• Thyroid C-cell tumors, including medullary thyroid cancer
• Severe gastrointestinal reactions
• Acute pancreatitis, which may result in death
• Acute kidney injury, often caused by dehydration due to gastrointestinal side effects
• Acute gallbladder disease 
• Low blood sugar, especially when taking insulin or a sulfonylurea at the same time
• Temporary worsening of diabetic retinopathy
• Hypersensitivity reactions, including potentially fatal swelling of the airways, throat, or tongue
• Pulmonary aspiration during procedures requiring anesthesia, which happens when food particles from retained food in the stomach are inhaled into the lungs

At this time, no serious side effects are unique to Zepbound or Foundayo. Both medications share the same risk profile when it comes to these rare but severe events. 

Foundayo and Zepbound drug interactions and warnings

Tell your healthcare provider about all other medications you take, as some of them can interact with Foundayo or Zepbound. 

Some drug interactions occur only with Foundayo, not Zepbound:

• Foundayo shouldn’t be taken with strong CYP3A4 inducers.
• A healthcare provider may need to increase your Foundayo dose if you take moderate CYP3A4 inducers.
• Foundayo shouldn’t exceed 9 mg once per day when taken with strong CYP3A4 inhibitors.
• No more than 20 mg of simvastatin should be taken per day when you also take Foundayo.

Other interactions apply to both medications: 

• If you take insulin or sulfonylureas, a healthcare provider may lower their dosages while you take Foundayo or Zepbound, since the combination can cause low blood sugar.
• Foundayo and Zepbound can change how oral medications are absorbed, so a healthcare provider may monitor or adjust the effectiveness of other prescriptions.
• Oral contraceptives may not be effective immediately after starting or increasing Foundayo or Zepbound, so another form of birth control should be used temporarily.

Who shouldn’t take Zepbound or Foundayo?

Foundayo and Zepbound haven’t been extensively studied in pregnant people, but animal studies suggest these medications could harm an unborn child. Tell your healthcare provider right away if you become pregnant or want to try becoming pregnant while taking either medication.

For breastfeeding, the data is limited. Zepbound was found in low or undetectable amounts in breast milk; still, Zepbound should be used with caution while nursing. Foundayo is not recommended for people who are breastfeeding because no lactation safety data is available. A healthcare provider can recommend a course of action if you want to take either medication while breastfeeding.

Foundayo shouldn’t be used in people with severe liver damage. Neither medication should be taken by people with a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome Type 2 (MEN 2).

Which medication is right for you?

Only a healthcare provider can help you decide whether Foundayo or Zepbound is right for you. There are many factors to consider, including your treatment goals, health history, budget, and personal preferences. 

“I’d consider Foundayo for a patient who strongly prefers an oral medication, is very needle-averse, or wants something easier to travel with,” says Dr. Ovalle. “I’d lean toward Zepbound when I’m looking for the strongest weight-loss effect, or when a patient is comfortable with weekly injections and wants less day-to-day medication burden.”

Expert takeaway

“While GLP-1 medications and combined GIP/GLP-1 medications are quite effective for weight loss and blood sugar control, as a gastroenterologist, I see frequent GI side effects of these meds,” says Jesse P. Houghton, MD, senior medical director of gastroenterology at Southern Ohio Medical Center and member of the SingleCare Medical Review Board. “I see more constipation than diarrhea with these meds, despite the initial studies showing more diarrhea. Nausea and bloating are quite common. My recommendation is always to start at a low dose and very slowly titrate upward as tolerated, knowing that a dose reduction may become necessary.” 

Frequently asked questions

Is Zepbound the same as Mounjaro?

Zepbound and Mounjaro are chemically identical, but have different FDA-approved indications. Only Mounjaro is approved to treat Type 2 diabetes, and only Zepbound is approved for weight loss.

What’s the difference between GLP-1s and dual agonists?

A dual agonist is any drug that binds to two different chemical receptors. Tirzepatide is a dual agonist because it binds to both GLP-1 and GIP receptors. 

Is Foundayo FDA approved?

Yes, Foundayo received FDA approval as a weight-loss drug on April 1, 2026.